Attila Lorincz, BsC (Dublin); PhD (Dublin)
Centre for Cancer Prevention
Email: firstname.lastname@example.org Telephone: Tel: +44 (0) 20 7882 3540
I received a doctorate in genetics from Trinity College, University of Dublin, Ireland. While a research fellow at the University of California, Santa Barbara I discovered that yeast cdc28 is a protein kinase and the prototype of human cell cycle cdk kinases.
During later research on human papillomavirus I found several important and novel carcinogenic HPV types, including HPV31, HPV35, HPV45, HPV52 and HPV56, and pioneered the initial use of HPV DNA testing for clinical diagnostics.
My team produced the first HPV test to be FDA-approved for patients in 1988 and for general population cervical precancer screening in 2003. My research output also includes the development of a simple robust HPV assay for resource-limited regions.
I was lead author on a large randomized clinical trial to validate self-sampling with HPV testing as an efficient screening approach to prevent cervical cancer in a developing region.
My ongoing research interests include the epigenomics of prostate, breast and cervical cancers. Recently my team have developed diagnostic and prognostic cancer biomarkers based on DNA methylation assays.
A new classifier combining HPV and human genes is a leading contender as a triage test for women infected by carcinogenic HPV types, while a different methylation classifier is prognostic of death in men with prostate cancer.
Work ongoing in the Molecular Epidemiology Laboratory is also focused on next generation deep sequencing and in elucidating the comparative epigenomic systems of selected human cancers.
I have written more than 240 peer-reviewed papers and 45 patents related to diagnostic and prognostic testing.
The American Venereal Disease Association gave me their 1994 Achievement Award.
Queen Mary University of London received THE TIMES Award 2012 for UK research project of the year, related to my MARCH randomized clinical trial.
Currently I serve as Editor-in-Chief of Expert Reviews in Molecular Diagnostics and as Associate Editor of Cancer Biomarkers.
- Cervical screening & HPV control
- Recurrence in DCIS, a study of clinico-pathological and molecular variables to identify prognostic and predictive factors
- Epidemiology of oral HPV infection, impact of immunisation and surveillance in young adults
- HPV studies of cervical screening & comparisons of cancer screening participation in the UK, Mexico, and USA
- HPV primary screening pilot-epidemiological evaluations
- Predictors 1&2, HPV testing in residual PreservCyt specimens and development of epigenetic biomarkers
- Predictors 3, HPV testing and DNA methylation in a UK screening population
- Predictors 5, self-sampling for HPV detection and methylation classifiers
- Prostate Cancer Programme, prognostic biomarkers
- Lazcano E, Lorincz AT, Torres L, Salmeron J, Cruz A, Rojas R, Hernandez P, Hernandez M. 2013. Specimen self-collection and HPV DNA screening in a pilot study of 100,242 women. Int J Cancer In Press.
- Lorincz AT, Brentnall AR, VasiljeviÄ‡ N, Scibior-Bentkowska D, Castanon A, Fiander A, Powell N, Tristram A, Cuzick J, Sasieni P. 2013. HPV16 L1 and L2 DNA methylation predicts high grade cervical intraepithelial neoplasia in women with mildly abnormal cervical cytology. Int J Cancer 133:637-44.
- Castle PE, Glass AG, Rush BB, Scott DR, Wentzensen N, Gage JC, Buckland J, Rydzak G, Lorincz AT, Wacholder S. 2012. Clinical Human Papillomavirus Detection Forecasts Cervical Cancer Risk in Women Over 18 Years of Follow-Up. J Clin Oncol. 30:3044-50.
- Mirabello L, Sun C, Ghosh A, Rodriguez AC, Schiffman M, Wentzensen N, Hildesheim A, Herrero R, Wacholder S, Lorincz AT, Burk RD. 2012. Methylation of Human Papillomavirus Type 16 Genome and Risk of Cervical Precancer in a Costa Rican Population. J Natl Cancer Inst. 104:556-65.
- Lazcano-Ponce E#, Lorincz AT#, Cruz-Valdes A, Salmeron J, Uribe P, Velasco-MondragÃ³n E, Hernandez Nevarez P, Diaz Acosta R, HernÃ¡ndez-Avila M. 2011. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial. (#Co-first authors). Lancet 378: 1868-73.
- You-lin Q, Sellors JW, Eder PS, Bao YP, Lim J, Zhao FH, Weigl B, Zhang WH, Peck RB, Li L, Chen F, Pan QJ, Lorincz AT. 2008. A new HPV-DNA test for cervical cancer screening in developing regions: Evaluation of clinical accuracy in rural China. Lancet Oncology 9:929-36.
ExpertiseAn experienced research investigator in molecular diagnostics, epidemiology and clinical trials with specific training and skills in genetics, clinical microbiology, including virology and bacteriology.
Current research interests and skills are in DNA methylation assays and in next generation deep sequencing for diagnostics in solid cancers.
Other current areas of related expertise include PCR assays, RNA assays, biomarker development, test validation, and medical statistics.
A skilled labora